High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

European Journal of Endocrinology

Volumn 151, Issue 1, 2004, Pages 107-112

  Welin, Staffan V ^a   Janson, Eva Tiensuu ^a   Sundin, Anders ^a   Stridsberg, Mats ^a   Lavenius, Erik ^b   Granberg, Dan ^a   Skogseid, Britt ^a   Öberg, Kjell E ^a   Eriksson, Barbro K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LONG ACTING DRUG; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; BIOCHEMISTRY; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; FEVER; GALLSTONE; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; INFECTION; MALE; MIDGUT; PATIENT MONITORING; PRIORITY JOURNAL; RADIOLOGICAL PROCEDURES; SYMPTOMATOLOGY; TUMOR GROWTH; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 4344699187     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510107     Document Type: Article

References (22)

1. Norheim I, Öberg K, Theodorsson-Norheim E, Lindgren PG, Lundqvist G, Magnusson A et al. Malignant carcinoid tumours. An analysis of 103 patients with regard to tumour localisation, hormone production, and survival. Annals of Surgery 1987 206 115-125.
2. Öberg K, Funa K & Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumours and carcinoid syndrome. New England Journal of Medicine 1983 309 129-133.
3. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973 179 77-79.
4. Yamada Y, Post SR, Wang K, Tager HS, Bell GI & Seino S. Cloning and functional characterisation of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. PNAS 1992 89 251-255.
5. Yamada Y, Reisine T, Law S, Ihara Y, Kubota A, Kagimoto S et al. Somatostatin receptors, an expanding gene family: cloning and functional characterisation of human SSTR3, a protein coupled to adenylyl cyclase. Molecular Endocrinology 1992 6 2136-2142.
6. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y et al. Cloning, functional expression and pharmacological characterisation of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochemical and Biophysical Research Communications 1993 195 844-852.
7. Chen C, Vincent JD & Clarke IJ. Ion channels and the signal transduction pathways in the regulation of growth hormone secretion. Trends in Endocrinology and Metabolism 1994 5 227-233.
8. Buscail L, Delesque N, Estève JP, Saint-Laurent N, Prats H, Clerc P et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. PNAS 1994 91 2315-2319.
9. Buscail L, Estève JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A-M et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. PNAS 1995 92 1580-1584.
10. Sharma K, Patel YC & Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor subtype 3. Molecular Endocrinology 1996 10 1688-1696.
11. Teijiro R, Rios R, Costoya JA, Castro R, Bello JL, Dovesa J et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cellular Physiology and Biochemistry 2002 12 31-38.
12. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L et al. Expression of somatostatin receptor subtypes 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumours. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Archiv 2002 440 461-475.
13. Kulaksiz H, Eissele R, Rössler D, Schultz S, Höllt V, Cetin Y et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002 50 52-60.
14. Lamberts SW, van der Lely AJ, De Herder WW & Hofland LJ. Octreotide. New England Journal of Medicine 1996 334 226-254.
15. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 1986 315 663-666.
16. Szende B, Schally AV, Comaru-Schally AM, Redding TW, Srkalovic G, Groot K et al. Cellular and molecular aspects of apoptosis in experimental tumours of animals treated with analogues of LHRH, somatostatin. In Apoptosis: The Molecular Basis of Cell Death. Current communications 3, pp 139-155. Eds LD Tomei & FO Cope. New York: Cold Spring Harbor Laboratory Press, 1991.
17. Eriksson B, Renstrup J, Imam H & Öberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours: clinical and biological effects. Annals of Oncology 1997 8 1041-1044.
18. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M et al. Somatostatin analogue phase 1 trials in neuroendocrine neoplasms. Acta Oncologica 1993 32 217-223.
19. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E et al. Induction of apoptosis in neuroendocrine tumours of the digestive system during treatment with somatostatin analogues. Acta Oncologica 1997 36 607-614.
20. Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B & Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumour tissue and intratumoural vessels in malignant endocrine pancreatic tumours. Medical Oncology 2003 20 59-67.
21. Gavrieli Y, Sherman Y & Ben-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. Journal of Cell Biology 1992 119 494-501.
22. R acetate in healthy subjects. Journal of Clinical Pharmacology 2000 40 475-481.